Meet the Hot New Coronavirus Vaccine Stock That's Already Bigger Than Inovio and Novavax
There's a new stock of a small biotech with a promising coronavirus vaccine now available to U.S. investors. CureVac (NASDAQ: CVAC) held its initial public offering (IPO) on the Nasdaq stock exchange last week. And that IPO raised some eyebrows.
CureVac expected the IPO share price would be between $14 and $16. The actual IPO price landed at the upper end of that range, but didn't stay there for long. CureVac stock opened at $44 per share on Friday, nearly three times higher than its IPO price.
The biotech stock has given up some of its jaw-dropping first-day gains. However, CureVac still claims a market cap of more than $12 billion. Here's what you'll want to know about the company that's already bigger than rival coronavirus vaccine makers Inovio Pharmaceuticals (NASDAQ: INO) and Novavax (NASDAQ: NVAX).
Source Fool.com
